{"links":{"html":"https://www.erudio.com/reports/origami-3-nct06750094","json":"https://www.erudio.com/reports/origami-3-nct06750094.json","markdown":"https://www.erudio.com/reports/origami-3-nct06750094.md","mcp":{"server":"https://mcp.erudio.com/mcp","tool":"get_report_card","arguments":{"slug":"origami-3-06750094"}},"request":"https://www.erudio.com/contact?report=origami-3-06750094"},"offer":{"cited_commentary_sources":14,"verified_hcp_statements":141,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"identities":{"adds":"Verified IDs for the clinicians in the report, led by the NPI, so a Medical Affairs team can connect the report's voices to the expert and insight records it keeps by NPI. For scientific and insight use inside the organization, not for promotional targeting or outreach. Every report already names and describes its speakers.","available_with":"12-month updates","cap_usd":750,"identity_verified_people":5,"optional":true,"price_per_verified_person_usd":15,"price_usd":75,"product":"updates-12-identities","terms":"Priced on the identity-verified people in the edition at purchase; people verified later in the term come at no charge."},"one_off_usd":750,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_tools":["create_order","get_order","recover_key"],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"optional","product":["edition","updates-3","updates-6","updates-12","updates-12-identities"],"report":"origami-3-nct06750094"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. If the order also returns pay_url, you can pay it yourself instead: POST pay_url answers 402 Payment Required with MPP or x402 offers for your payment client. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=origami-3-06750094","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/origami-3-nct06750094","renewal":"Subscriptions are prepaid and do not renew automatically.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"focused","size_rule":"Focused: 1–150 verified statements","updates_usd":{"3_months":1300,"6_months":1900,"12_months":2600},"volume_discounts":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-10-19T16:45:02.452777Z","notify_subscribers":false,"status":"new","summary":{"reason":"Initial accepted edition has no weekly change log.","status":"not_applicable"}},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":11,"no_commentary_found":2},"aspects":[{"claim_count":1,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":1,"title":"Primary endpoint: Progression-Free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR)"},{"claim_count":0,"coverage":"no_commentary_found","id":"T2","registry_field":"outcomesModule.primaryOutcomes[1]","source_count":0,"title":"Primary endpoint: Overall Survival (OS)"},{"claim_count":0,"coverage":"no_commentary_found","id":"T3","registry_field":"outcomesModule.secondaryOutcomes","source_count":0,"title":"Secondary endpoints"},{"claim_count":8,"coverage":"discussed","id":"T4","registry_field":"conditionsModule","source_count":3,"title":"Population and setting"},{"claim_count":4,"coverage":"discussed","id":"T5","registry_field":"armsInterventionsModule.armGroups","source_count":4,"title":"The comparison"},{"claim_count":5,"coverage":"discussed","id":"T6","registry_field":"outcomesModule","source_count":2,"title":"Safety and tolerability"},{"claim_count":7,"coverage":"discussed","id":"T7","registry_field":"designModule","source_count":8,"title":"Design and conduct"},{"claim_count":20,"coverage":"discussed","id":"A1","source_count":6,"title":"EGFR/MET rationale and interpretation of early-phase evidence"},{"claim_count":8,"coverage":"discussed","id":"A2","source_count":1,"title":"Prior biologic exposure and anti-EGFR rechallenge sequencing"},{"claim_count":12,"coverage":"discussed","id":"A3","source_count":4,"title":"Molecular confirmation and selective repeat testing"},{"claim_count":8,"coverage":"discussed","id":"A4","source_count":1,"title":"ctDNA access, payment and equitable treatment selection"},{"claim_count":14,"coverage":"discussed","id":"A5","source_count":2,"title":"Toxicity-constrained alternatives and selected immunotherapy"},{"claim_count":8,"coverage":"discussed","id":"A6","source_count":7,"title":"Enrollment, referral and public evidence-status communication"}],"counts":{"cited_sources":14,"claims_by_expression_type":{"comparison":13,"experience":12,"interpretation":20,"opinion":18,"primary_context":4,"question":15,"restatement":36,"uncertainty":4,"unspecified":19},"claims_by_kind":{"interpretation":5,"source_observation":136},"clinician_statements":89,"evidence_units":82,"findings":7,"people_cited":9,"people_identity_verified":5,"people_total":11,"screened_sources":14,"verified_claims":141},"depth":"standard","findings_index":[{"id":"F1","structure":{"claims":9,"claims_by_group":{"comparisons":1,"experience":2,"questions":2,"restated":2,"views":2},"has_counterview":false,"limitations":3,"links":{"context":1,"support":20},"ma_question":true,"named_voices":3,"passages":8,"sources":2,"sources_by_kind":{"media":2}},"title":"Right-sided activity prompted trial discussion, not a conclusion of superior second-line benefit"},{"id":"F2","structure":{"claims":14,"claims_by_group":{"comparisons":0,"experience":4,"questions":3,"restated":1,"views":6},"has_counterview":false,"limitations":4,"links":{"context":3,"support":16},"ma_question":true,"named_voices":1,"passages":10,"sources":2,"sources_by_kind":{"media":2}},"title":"Prior intolerance and patient preferences could redirect treatment away from chemotherapy rechallenge"},{"id":"F3","structure":{"claims":20,"claims_by_group":{"comparisons":3,"experience":0,"questions":3,"restated":7,"views":7},"has_counterview":true,"limitations":4,"links":{"context":6,"support":23},"ma_question":true,"named_voices":4,"passages":12,"sources":6,"sources_by_kind":{"commentary":1,"media":5}},"title":"The EGFR/MET rationale and early activity generated interest while leaving validation open"},{"id":"F4","structure":{"claims":12,"claims_by_group":{"comparisons":0,"experience":2,"questions":1,"restated":4,"views":5},"has_counterview":false,"limitations":4,"links":{"context":3,"support":21},"ma_question":true,"named_voices":2,"passages":11,"sources":4,"sources_by_kind":{"media":4}},"title":"Molecular confirmation matters, but repeat-testing schedules remained experience-based"},{"id":"F5","structure":{"claims":8,"claims_by_group":{"comparisons":1,"experience":0,"questions":1,"restated":3,"views":3},"has_counterview":false,"limitations":4,"links":{"context":0,"support":8},"ma_question":true,"named_voices":0,"passages":2,"sources":1,"sources_by_kind":{"media":1}},"title":"Prior biologic exposure and rechallenge timing complicate where the study fits"},{"id":"F6","structure":{"claims":8,"claims_by_group":{"comparisons":1,"experience":0,"questions":2,"restated":1,"views":4},"has_counterview":false,"limitations":3,"links":{"context":1,"support":10},"ma_question":true,"named_voices":1,"passages":2,"sources":1,"sources_by_kind":{"media":1}},"title":"ctDNA-guided selection was limited by testing access, drug access and responsibility for payment"},{"id":"F7","structure":{"claims":9,"claims_by_group":{"comparisons":1,"experience":0,"questions":0,"restated":7,"views":1},"has_counterview":false,"limitations":4,"links":{"context":2,"support":10},"ma_question":true,"named_voices":6,"passages":9,"sources":8,"sources_by_kind":{"commentary":6,"media":2}},"title":"Enrollment advocacy must be distinguished from public assertions of successful trial results"}],"medical_affairs_question":"What evidence and toxicity information would clinicians need to discuss a trial for right-sided disease without equating response with durable benefit?","sections":{"analysis":[{"id":"section-1","level":2,"title":"Right-sided disease: exploratory trial interest with an outcome qualification"},{"id":"section-2","level":2,"title":"Intolerance and preferences: reasons not to return to a regimen belong beside the alternatives"},{"id":"section-3","level":2,"title":"EGFR/MET and early-phase evidence: a rationale to test, not completed validation"},{"id":"section-4","level":2,"title":"Molecular work-up: classification confidence and selective reassessment"},{"id":"section-5","level":2,"title":"Sequencing and rechallenge: true wild-type reassessment and time off anti-EGFR treatment"},{"id":"section-6","level":2,"title":"ctDNA access: a condition of acting on molecular information"},{"id":"section-7","level":2,"title":"Enrollment and public discussion: distinguish referral signals from result assertions"},{"id":"section-8","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, randomized, parallel, phase3","trial_dimensions":[{"findings":[{"id":"F1","shared_claims":1}],"id":"T1","label":"Primary endpoint: Progression-Free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR)"},{"findings":[],"id":"T2","label":"Primary endpoint: Overall Survival (OS)"},{"findings":[],"id":"T3","label":"Secondary endpoints"},{"findings":[{"id":"F1","shared_claims":7},{"id":"F7","shared_claims":1}],"id":"T4","label":"Population and setting"},{"findings":[{"id":"F1","shared_claims":2},{"id":"F7","shared_claims":2}],"id":"T5","label":"The comparison"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F2","shared_claims":4}],"id":"T6","label":"Safety and tolerability"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F3","shared_claims":1},{"id":"F5","shared_claims":1},{"id":"F7","shared_claims":4}],"id":"T7","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-10-19T16:45:02.452777Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-10-19T16:55:37Z","record_hash":"81c76409692f562c2152f1984c51c88c19e0eac468f6594ce3f6bb6720e006e4","release_hash":"3e78d98559705be29c2e076c532c55ff5da0b5f63707a79aab866fca202d9ef3","report_id":"erudio-nct06750094","run_id":"2cbe22ec-f514-426c-ad60-805ad3f0eb1f","schema_version":"5.0","slug":"origami-3-06750094","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"OrigAMI-3 asks whether amivantamab plus FOLFIRI improves outcomes over cetuximab or bevacizumab plus FOLFIRI in second-line RAS/BRAF-wild-type advanced colorectal cancer. Clinicians in the sources reviewed for this edition discuss trial participation conditionally and question how the study fits treatment sequencing. These clinicians express interest in the EGFR/MET rationale while scrutinizing second-line benefit in right-sided disease. Comparative benefit and the approach’s eventual treatment role remain open questions in their commentary.","meta_description":"14 sources screened · 141 verified statements (89 from speakers with a confirmed clinical role) from 14 sources · 7 findings. Updated Oct 19, 2026.","person_names_policy":"role_only","sample_findings":[{"cited_claim_ids":["claim-92b0813b92b46e7f24ef"],"id":"F3","paraphrase":"A podcast speaker asked whether acquired KRAS/NRAS mutations could explain resistance following progression, and what might enable amivantamab or EGFR targeting to overcome it.","publication_caveats":{"reason":"Publication-specific caveats are not stated in the sources reviewed for this edition.","status":"not_set"},"source_channel":"podcast","source_date":"2026-02-11","title":"The EGFR/MET rationale and early activity generated interest while leaving validation open"},{"cited_claim_ids":["claim-dac34688eb229a653dd5","claim-6693e90a89cc2e4d38be"],"id":"F1","paraphrase":"In a YouTube case discussion, a speaker asked how to choose second-line treatment, whether an amivantamab study could be considered and which patient characteristics would matter for eligibility.","publication_caveats":{"reason":"Publication-specific caveats are not stated in the sources reviewed for this edition.","status":"not_set"},"source_channel":"youtube","source_date":"2026-07-01","title":"Right-sided activity prompted trial discussion, not a conclusion of superior second-line benefit"}]},"publication":{"approved_at":"2026-10-19T16:55:37Z","approved_by":"Erudio publisher","corrections":[],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":14},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","Some clinician views in the sources used in this report are not yet captured as evidence in this edition; the next refresh takes them up.","Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.","Out of scope: 7 passages in the reviewed sources discuss other trials or topics outside this report's scope; they are not part of this edition.","83 statements in the sources reviewed for this edition discuss other treatment settings or topics unrelated to this trial's question and are not included.","Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.","The sources reviewed do not represent all HCPs or all public discussion. Discussion that did not use recognizable trial names or identifiers may be missing.","Some recordings reproduce substantially overlapping panel material. Source counts cannot be interpreted as independent HCP counts or consensus.","No protocol document or publication reporting results for the exact OrigAMI-3 trial was available. Earlier OrigAMI-1 observations and trial-design descriptions do not establish OrigAMI-3 efficacy or safety.","Several consequential panel replies remain unidentified. Clinical roles for Kotani, Di Giacomo and A.n.n. are not established in the sources reviewed; unidentified social accounts are not confirmed HCPs.","The publisher posts relay talks and do not establish the advertised presenters' detailed clinical assessments. Post and publication dates do not establish session dates or changes of opinion.","Eng's right-sided case did not state BRAF status. The separate toxicity-constrained case and reported immunotherapy outcome should not be assumed to establish OrigAMI-3 eligibility.","The meaning and assay behind ctDNA-negative rechallenge selection were not specified. Favorable ctDNA sensitivity comments concerned untreated patients, while repeat-NGS views were explicitly experience-based.","Some potentially relevant discussion was not fully assessed, particularly treatment cessation after response and local treatment of residual lesions. Conclusions about the complete range of clinician views on those decisions are therefore limited.","Recruitment and implementation statements describe the sources' observations at the time. They do not independently confirm current enrollment, reimbursement or country-wide testing practice."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":0,"other":0,"podcast":2,"publication":0,"registry":0,"regulatory":0,"x_thread":7,"x_video":0,"youtube":5},"by_evidence_role":{"commentary":14},"count":14,"evidence_window":{"end":"2026-09-18","start":"2024-12-27"},"retrieval_snapshot":"2026-10-19T14:57:14.925348Z","timeline":[{"count":1,"week":"2024-W52"},{"count":1,"week":"2025-W05"},{"count":1,"week":"2025-W13"},{"count":1,"week":"2025-W23"},{"count":1,"week":"2026-W02"},{"count":1,"week":"2026-W07"},{"count":1,"week":"2026-W09"},{"count":1,"week":"2026-W10"},{"count":1,"week":"2026-W17"},{"count":1,"week":"2026-W22"},{"count":1,"week":"2026-W27"},{"count":1,"week":"2026-W28"},{"count":1,"week":"2026-W31"},{"count":1,"week":"2026-W38"}],"undated_sources":0},"quote_policies":[{"id":"clinicaltrials:NCT06750094:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT06750094:context","quote_policy":"short_quote_link_out"},{"id":"openfda:9e58b045-e352-4f62-99bf-77fae1bebc69:20260617","quote_policy":"short_quote_link_out"},{"id":"openfda:8bc6397e-4bd8-4d37-a007-a327e4da34d9:20260416","quote_policy":"short_quote_link_out"},{"id":"openfda:4cdcccda-7b9a-49d0-ac50-f4605a3c0ebe:20260821","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:6949bb","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:7b7ee3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1872781761522139286:5cd5e5c3-d1d8-4978-9832-8aac6ae30aa4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1905351532146778391:ce81e035-002a-40e5-ba22-f875eeac2c17","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1930278554136117555:ae07c805-e519-4575-bdd8-f937b82961fb","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2010143914506981745:911e03f6-c5b8-47f9-89fd-3f409ac723f4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2025898356355056079:88fbd4b5-03af-40d3-b2d8-873aaa9adc23","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2047511262565724173:08f741f2-5717-458c-b7e6-2da7e7cd2522","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2100957653392564335:fd1f4a03-2923-40a3-8f98-7227ecda790b","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:94AnzPafFCc","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:QALWmfdE7VQ","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:R0rexaM5ZCk","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:SsfzfZgRgGs","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:Ul28psQyIEc","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":0,"other":0,"podcast":2,"publication":0,"registry":0,"regulatory":0,"x_thread":7,"x_video":0,"youtube":5},"by_evidence_role":{"commentary":14},"count":14,"evidence_window":{"end":"2026-09-18","start":"2024-12-27"},"retrieval_snapshot":"2026-10-19T14:57:14.925348Z","timeline":[{"count":1,"week":"2024-W52"},{"count":1,"week":"2025-W05"},{"count":1,"week":"2025-W13"},{"count":1,"week":"2025-W23"},{"count":1,"week":"2026-W02"},{"count":1,"week":"2026-W07"},{"count":1,"week":"2026-W09"},{"count":1,"week":"2026-W10"},{"count":1,"week":"2026-W17"},{"count":1,"week":"2026-W22"},{"count":1,"week":"2026-W27"},{"count":1,"week":"2026-W28"},{"count":1,"week":"2026-W31"},{"count":1,"week":"2026-W38"}],"undated_sources":0}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"conferences":{"reason":"No conferences in source metadata.","status":"none"},"drugs":[{"brand_names":["Rybrevant"],"label":"amivantamab","slug":"amivantamab"},{"brand_names":["Erbitux"],"label":"cetuximab","slug":"cetuximab"},{"brand_names":["Avastin"],"label":"bevacizumab","slug":"bevacizumab"},{"brand_names":["Adrucil","Favlyxa"],"label":"fluorouracil","slug":"fluorouracil"},{"reason":"Unmapped registry intervention: leucovorin calcium/levoleucovorin","status":"unmapped"},{"brand_names":["Camptosar"],"label":"irinotecan","slug":"irinotecan"}],"indications":[{"reason":"Unmapped registry condition: Colorectal Neoplasms","status":"unmapped"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":{"reason":"Conditions lack a therapeutic-area mapping.","status":"unmapped"}},"trial":{"acronym":"OrigAMI-3","aliases":["OrigAMI-3","A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy","A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Recurrent, Unresectable or Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy"],"brief_title":"A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy","collaborators":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"conditions":["Colorectal Neoplasms"],"enrollment":{"count":700,"type":"ESTIMATED"},"interventions":[{"name":"Amivantamab","synonyms":["JNJ-61186372"],"type":"BIOLOGICAL"},{"name":"Cetuximab","synonyms":["Erbitux"],"type":"BIOLOGICAL"},{"name":"Bevacizumab","synonyms":["Avastin"],"type":"BIOLOGICAL"},{"name":"5-fluorouracil","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Leucovorin calcium/Levoleucovorin","synonyms":["Folinic acid"],"type":"DRUG"},{"name":"Irinotecan","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"}],"nct_id":"NCT06750094","official_title":"A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Recurrent, Unresectable or Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy","overall_status":"RECRUITING","phase":["PHASE3"],"primary_completion_date":{"date":"2027-12-15","type":"ESTIMATED"},"primary_endpoints":[{"description":"PFS is defined as the time from randomization until the date of objective disease progression or death (due to any cause), whichever comes first, as assessed by BICR using response evaluation criteria in solid tumors (RECIST) version (v)1.1. Participants who have not progressed or have not died at the time of analysis will be censored at their last evaluable RECIST v1.1 assessment date.","measure":"Progression-Free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR)","timeFrame":"Up to 2 years 1 month"},{"description":"OS is defined as the time from the date of randomization to the date of participant's death due to any cause.","measure":"Overall Survival (OS)","timeFrame":"Up to 4 years 4 months"}],"registry_last_updated":"2026-09-25","registry_url":"https://clinicaltrials.gov/study/NCT06750094","short_name":"OrigAMI-3","short_name_basis":"registry_acronym","sponsor":"Janssen Research & Development, LLC","start_date":{"date":"2024-12-12","type":"ACTUAL"},"study_design":"interventional, randomized, parallel, phase3","study_ids":[{"id":"61186372COR3002","type":"sponsor_study_id"},{"domain":"EUCT number","id":"2024-513853-66-00","type":"registry"}],"study_type":"INTERVENTIONAL"}}}